139756-02-8

Basic information

• Product Name: 4-Amino-1-methyl-3-propyl-5-pyrazolecarboxamide
• Synonyms: 4-Amino-1-methyl-3-propyl-5-pyrazolecarboxam;4-amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide HCl;4-Amino-1-methyl-3-n-propyl-5-pyrazolecarboxamide,4-Amino-2-methyl-5-propyl-2H-pyrazole-3-carboxylic acid amide;Sildenafil AMino AMide IMpurity;1H-Pyrazole-5-carboxaMide,4-aMino-1-Methyl-3-propyl-;4-Amino-1-methyl-3-n-propyl-5-pyrazolecarboxamide 96%;4-amino-2-methyl-5-propyl-3-pyrazolecarboxamide;4-amino-2-methyl-5-propyl-pyrazole-3-carboxamide
• CAS NO: 139756-02-8
• Molecular Formula: C₈H₁₄N₄O
• Molecular Weight: 182.22
• EINECS: 1533716-785-6
• Product Categories: Nucleotides and Nucleosides;Bases & Related Reagents;Nucleotides;Amines;Heterocycles;Heterocyclic Compounds
• Mol File: 139756-02-8.mol
• Article Data: 20

Chemical Properties

• Melting Point: 98-101 °C(lit.)
• Boiling Point: 325.9 ºC at 760 mmHg
• Flash Point: 150.9 ºC
• Appearance: /
• Density: 1.32 g/cm³
• Vapor Pressure: 0.000223mmHg at 25°C
• Refractive Index: 1.618
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Ethyl Acetate, Methanol
• PKA: 15.30±0.50(Predicted)
• CAS DataBase Reference: 4-Amino-1-methyl-3-propyl-5-pyrazolecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-1-methyl-3-propyl-5-pyrazolecarboxamide(139756-02-8)
• EPA Substance Registry System: 4-Amino-1-methyl-3-propyl-5-pyrazolecarboxamide(139756-02-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 139756-02-8(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Uses

Different sources of media describe the Uses of 139756-02-8 differently. You can refer to the following data:
1. An impurity in the synthesis of Sildenafil.
2. A potent hypolipidemic agent. A possible inhibitor of phosphodiesterase 1

InChI:InChI=1/C8H14N4O/c1-3-4-5-6(9)7(8(10)13)11-12(5)2/h3-4,9H2,1-2H3,(H2,10,13)

Upstream product

• 139755-99-0 1-methyl-3-propyl-1 H-pyrazole-5-carboxylic acid 
• 360068-47-9 1-methyl-4-nitro-3-propyl-1H-pyrazole-5-carbonyl chloride 
• 92945-27-2 ethyl 3-propyl-1H-pyrazole-5-carboxylate 
• 107-87-9 2-Pentanone 
• 304435-81-2 [N'-(1-cyano-butyl)-N-methyl-hydrazino]-acetic acid ethyl ester 
• 139756-00-6 1-methyl-2-nitro-3-propyl-1H-pyrazole-5-carboxylic acid 
• 133261-07-1 1-Methyl-3-n-propylpyrazole-5-carboxylic acid ethyl ester 
• 36983-31-0 ethyl 3-butyrylpyruvate 
• 139756-01-7 1-methyl-4-nitro-3-propyl-1H-pyrazole-5-carboxamide 
• 67-56-1 methanol 
• 304435-83-4 4-amino-2-methyl-5-propyl-2H-pyrazole-3-carboxylic acid ethyl ester 

Downstream Products

• 200575-15-1 4-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)benzamido]-1-methyl-3-propyl-1H-pyrazole-5-carboxamide 
• 139756-21-1 5-(2-ethoxy)-phenyl-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one 
• 960009-37-4 5-[2-ethoxycarbonyloxy-5-(4-methyl-piperazine-1-sulfonyl)-phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
• 1093065-15-6 5-[2-ethoxy-5-(4-methylpiperazin-1-yl-sulphonyl)phenyl]-1-methyl-3-n-propyl-1-hydro-7-ethoxypyrazolo[4,3-d]pyrimidine 
• 1363693-50-8 5-[2-hydroxy-5-(4-methylpiperazine-1-yl-sulphonyl)phenyl]-1-methyl-3-n-propyl-1-hydro-7-ethoxypyrazolo[4,3-d]pyrimidine 
• 1363693-47-3 5-[2-ethoxy-5-(4-methylpiperazine-1-yl-sulphonyl)phenyl]-1-methyl-3-n-propyl-6-ethyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
• 139755-83-2 viagra 
• 1639453-62-5 5-(4-chlorophenyl)-1-methyl-7-phenyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine 
• 1639453-63-6 5-(4-chlorophenyl)-7-(2-methoxyphenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine 
• 1639453-64-7 5-(4-chlorophenyl)-1-methyl-3-propyl-7-(p-tolyl)-1H-pyrazolo[4,3-d]pyrimidine 
• 1639453-65-8 2-{[5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino}acetic acid 
• 1639453-69-2 5-(4-chlorophenyl)-1-methyl-3-propyl-1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidin-7(8H)-one 

Relevant articles and documents

Preparation method of sildenafil citrate

The invention discloses a preparation method of sildenafil. The method comprises the following steps: activating an intermediate compound B in an aprotic solvent by using thionyl chloride, reducing with 1-methyl-4-nitro-3-propyl-1H-pyrazole-5-formamide in a zinc powder-ammonium chloride system in the presence of an acid-binding agent to obtain an intermediate compound E, and condensing to obtain an intermediate compound C; and cyclizing the intermediate compound C in an alcohol solvent under an alkaline condition to prepare sildenafil. The preparation method disclosed by the invention is short in reaction time, greatly shortens the production period so as to reduce the production cost, and is simple in operation and suitable for large-scale production.

Preparation method of sildenafil citrate

The invention belongs to the field of chemical drugs, and in particular relates to a preparation method of sildenafil citrate. The invention provides the preparation method of sildenafil citrate. Thepreparation method comprises the following steps: a) adding a compound of a structure as shown in a formula (I) and thionyl chloride into chlorosulfonic acid, and carrying out a sulfonation reaction to generate a compound of a structure as shown in a formula (II); b) dissolving the compound of the structure as shown in the formula (II) in dichloromethane and adding N-methyl piperazine to carry outa substitution reaction at 20-30 DEG C to obtain sildenafil; and c) adding citric acid into a sildenafil aqueous solution to adjust the pH value for a salt forming reaction so as to obtain the sildenafil citrate. Experimental results verify that the sildenafil citrate prepared by the preparation method is high in yield and high in purity.

NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT

Novel compounds for use in cognition improvement It relates to certain compounds having a polycyclic structure and a -(C=O)NRaRb moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases.